A forest plot of these 90% confidence intervals, as well as the corresponding metoprolol results, is provided in Fig. 4. From this plot, the overall lack of any effect of metoprolol or redosing on pyronaridine exposure is apparent.
As in previous studies [19], the influence of SHS on inflammatory and hemostatic markers starts at very low levels of exposure (being apparent well below 0.7 ng/ml, the cotinine level associated with increased CHD risk in our earlier study [5]) and are disproportionate to exposure levels.
After stratification by SES, the differences in attained weight and height attributable to high arsenic exposure were apparent only among those with low SES, while the attributable change due to high cadmium exposure was somewhat attenuated in the high-SES group compared with the low-SES group.
To conceptualize 'urban transport justice', the paper discusses three dimensions where injustices are apparent: Exposure to traffic risks and pollutants; distribution of space; and valuation of transport time.
In fact, the developmental neurotoxicity of parathion emerges only at doses exceeding the threshold for overt toxicity, whereas the corresponding effects of chlorpyrifos and diazinon are apparent at exposures below the maximum tolerated dose.
Significant exposure trends were apparent for the peak exposure, the cumulated exposure and the duration of exposure metric (Hauptmann et al. 2004).
Morphological changes, evident using phase-contrast imaging, are apparent upon DMSO exposure and include the formation of membrane extensions resulting in the loss of uniformity of shape.
The post hoc analysis categorising cumulative exposure into 1 day to 2 years, 2 4 years and ≥4 years suggests that some threshold of cumulative exposure may be needed before effects are apparent.
In general, we observed the largest associations with prenatal exposure to BDE-100, and the associations with prenatal exposures were still apparent, albeit not consistently significant, in our smaller sample examined at 72 months of age.
The difference between the standard Cox model and Fine and Gray model (which accounts for competing risks and aims to estimate the prognostic impact of exposures on outcomes) was apparent only for participants with diabetic nephropathy.
In the more stable analysis, the ORs for myeloid leukaemia showed little difference in the FA exposure groups and thus, no exposure-dependent trend was apparent (Cole et al. 2010; Golden 2011; Nielsen and Wolkoff 2010; Rhomberg et al. 2011).
